FIELD: biotechnology.
SUBSTANCE: kit for detecting antibodies of classes M and G to the nucleocapsid (Nc) and the receptor-binding domain of the spike protein of the SARS-CoV-2 coronavirus in a sample of human biological fluid is described. The kit contains an absorbent membrane for applying a sample and a membrane for applying a conjugate with applied and dried conjugates of the recombinant coronavirus antigen SARS-CoV-2, where the membrane for the sample is impregnated with a buffer solution, which is an aqueous solution prepared from the components in the following ratio, wt. %: tris-hydroxymethyl aminomethane 1%, tris-hydroxymethyl aminomethane hydrochloride 0.1%, sodium caseinate salt 1%, polyvinylpyrrolidone 0.1%, sodium azide 2%, tween-20 1%, mouse antibodies against human erythrocytes 0.02 %, the membrane for the conjugate is impregnated with an aqueous solution prepared from the components in the following ratio, wt. %: anhydrous sodium hydrogen phosphate 1.5%, polyvinyl alcohol 0.5%, bovine serum albumin 1%, Triton-X-100 0.1%, sodium azide 2%.
EFFECT: obtaining an accurate diagnostic result while using the invention.
1 cl, 3 dwg, 11 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
STRAIN OF HCOV-19/RUSSIA/OMSK-202118-1707/2020 OF SARS-COV-2 CORONAVIRUS, IMMUNOSORBENT CONTAINING PURIFIED WHOLE VIRION ANTIGEN OBTAINED ON BASIS OF SPECIFIED STRAIN AND ISA TEST SYSTEM FOR DETECTING ANTIBODIES OF CLASSES M, G AND A TO SARS CORONAVIRUS-COV-2 USING SPECIFIED IMMUNOSORBENT | 2021 |
|
RU2752862C1 |
METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS | 2020 |
|
RU2730897C1 |
METHOD FOR DETECTING INFECTION OF HUMANS AND ANIMALS WITH SARS CoV 2 AND A DIAGNOSTIC KIT FOR IMPLEMENTING THE METHOD | 2021 |
|
RU2776295C1 |
TEST SYSTEM AND METHOD FOR DIFFERENTIAL DETECTION OF ANTIBODIES TO SARS-COV-2 | 2021 |
|
RU2754340C1 |
METHOD FOR ENZYME IMMUNOASSAY DETERMINATION OF THE LEVEL OF ANTIGEN-RECOGNIZING B-LYMPHOCYTE RECEPTORS REPRESENTED BY MEMBRANE-SPECIFIC RBD PROTEIN SARS-COV-2, IgG ANTIBODIES | 2021 |
|
RU2760438C1 |
METHOD FOR CARRYING OUT AN ENZYME-LINKED IMMUNOSORBENT ASSAY FOR THE DETECTION OF ANTIBODIES IN A HUMAN BIOLOGICAL SAMPLE SPECIFIC TO THE SARS-COV2 HUMAN CORONAVIRUS, A TEST SYSTEM | 2021 |
|
RU2759149C1 |
METHOD FOR QUANTITATIVE DETERMINATION OF CONCENTRATION OF S-ANTIGEN IN WHOLE-VIRION INACTIVATED ADSORBED ON ALUMINUM HYDROXIDE, SUBUNIT BASED ON S-PROTEIN, RECOMBINANT OR POLYPEPTIDE, CONTAINING RBD DOMAIN OF SPIKE PROTEIN OF SARS-COV VIRUS FOR PREVENTION OF CORONAVIRUS INFECTION COVID-19 AND/OR OTHER CORONAVIRUS INFECTIONS | 2023 |
|
RU2825291C1 |
Method for producing Chinese hamster ovary cell strain, being a producer of recombinant SARS-CoV-2 virus protein RBD, Chinese hamster ovary cell strain, producer of recombinant SARS-CoV-2 protein RBD, method for producing recombinant SARS-CoV-2 virus protein RBD, test system for enzyme immunoassay of human serum or plasma, and use thereof | 2020 |
|
RU2723008C1 |
METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
METHOD FOR DETERMINING COMPLEMENT-ACTIVATING FUNCTION OF SARS-CoV-2 ANTIBODIES FOR PREDICTING SEVERITY OF COVID-19 | 2023 |
|
RU2818351C1 |
Authors
Dates
2023-12-04—Published
2023-01-19—Filed